Unleash Immuno Oncolytics Acquires 9.94% Stake in TransCode Therapeutics (RNAZ)

Unleash Immuno Oncolytics, Inc. has filed a Schedule 13G with the SEC, reporting a new significant ownership stake in TransCode Therapeutics, Inc. (RNAZ). As of the event date on July 23, 2026, the reporting person acquired 300,000 shares of common stock, representing a 9.94% ownership interest in the company. This filing marks a major increase from a previous zero-holding position, establishing Unleash Immuno Oncolytics as a substantial shareholder. The acquisition was made for investment purposes, as indicated by the Rule 13d-1(c) filing status and the certification that the shares were not acquired to influence or change the control of the issuer. The reporting person, a Delaware corporation based in Miami, FL, holds sole voting and dispositive power over all 300,000 shares. This transaction highlights a significant new institutional interest in TransCode Therapeutics, a Boston-based biotechnology firm.